Skip to content
10-Q

Quarterly Report

CTI BIOPHARMA CORP

0000891293-23-000015

← back to feed
Filed
May 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 4, 2023 131.88M sh
Shares Diluted Q1 2023 · Mar 31, 2023 131.57M sh
Shares Diluted Q1 2023 · Mar 31, 2022 99.83M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$31.1M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$29.98M
Short Term Debt Q1 2023 · Mar 31, 2023 $48.08M
Short Term Debt Q1 2023 · Dec 31, 2022 $47.94M
Short Term Investments Q1 2023 · Mar 31, 2023 $34.8M
Short Term Investments Q1 2023 · Dec 31, 2022 $49.52M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $24.21M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $30.42M
Current Liabilities Q1 2023 · Mar 31, 2023 $68.23M
Current Liabilities Q1 2023 · Dec 31, 2022 $81.13M
Total Liabilities Q1 2023 · Mar 31, 2023 $137.62M
Total Liabilities Q1 2023 · Dec 31, 2022 $143.5M
Current Assets Q1 2023 · Mar 31, 2023 $86.45M
Current Assets Q1 2023 · Dec 31, 2022 $99.4M
Total Assets Q1 2023 · Mar 31, 2023 $112.27M
Total Assets Q1 2023 · Dec 31, 2022 $125.93M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.10
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.37
Eps Basic Q1 2023 · Mar 31, 2023 −$0.10
Eps Basic Q1 2023 · Mar 31, 2022 −$0.37
Sga Expense Q1 2023 · Mar 31, 2023 $21.91M
Sga Expense Q1 2023 · Mar 31, 2022 $18.05M
Net Income Q1 2023 · Mar 31, 2023 −$13.42M
Net Income Q1 2023 · Mar 31, 2022 −$37.18M
Operating Income Q1 2023 · Mar 31, 2023 −$9.23M
Operating Income Q1 2023 · Mar 31, 2022 −$35.1M
Cost Of Revenue Q1 2023 · Mar 31, 2023 $1.22M
Cost Of Revenue Q1 2023 · Mar 31, 2022 $278K
Revenue Q1 2023 · Mar 31, 2023 $24.12M
Revenue Q1 2023 · Mar 31, 2022 $2.3M